Connie Marras

Predicting motor decline and disability in Parkinson disease: a systematic review.

Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.

Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort.

Smell identification ability in twin pairs discordant for Parkinson's disease.

Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings.

Atypical antipsychotics and parkinsonism.

Antipsychotic use in older adults with Parkinson's disease.

Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial.

Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain.

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.

LRRK2 and Parkin mutations in a family with parkinsonism-Lack of genotype-phenotype correlation.

Urate as a predictor of the rate of clinical decline in Parkinson disease.

A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.

Rotenone, paraquat, and Parkinson's disease.

Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts.

The curious case of phenocopies in families with genetic Parkinson's disease.

Solvent exposures and Parkinson disease risk in twins.

Genetics meets environment: evaluating gene-environment interactions in neurologic diseases.

Head injury, α-synuclein Rep1, and Parkinson's disease.

Dihydropyridine calcium channel blockers and the progression of parkinsonism.

Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples.

Improvement of apathy after levofloxacin treatment: an N-of-1 study.

Piecing together the puzzle of progression and mortality in Parkinson's disease.

Protocol for a systematic review of prognosis after mild traumatic brain injury: an update of the WHO Collaborating Centre Task Force findings.

Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.

Investigation of C9orf72 in 4 Neurodegenerative Disorders.

Author reply to Holford, Vu and Nutt regarding 'Piecing together the puzzle of progression and mortality in Parkinson's disease'.

Genetic modification of the association of paraquat and Parkinson's disease.

Management of neuropsychiatric symptoms in long-term care residents with Parkinson's disease: a retrospective cohort study.

Measuring mild cognitive impairment in patients with Parkinson's disease.

Dietary fat intake, pesticide use, and Parkinson's disease.

Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy.

Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment.

Systematic review of the risk of Parkinson's disease after mild traumatic brain injury: results of the International Collaboration on Mild Traumatic Brain Injury Prognosis.

Systematic review of the risk of dementia and chronic cognitive impairment after mild traumatic brain injury: results of the International Collaboration on Mild Traumatic Brain Injury Prognosis.

Small intestinal bacterial overgrowth in Parkinson's disease.

Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses.

Reluctance to start medication for Parkinson's disease: a mutual misunderstanding by patients and physicians.

The tools of the trade: a state of the art "How to Assess Cognition" in the patient with Parkinson's disease.

The complexities of hormonal influences and risk of Parkinson's disease.

Peptidoglycan recognition protein genes and risk of Parkinson's disease.

Initiating dopaminergic treatment in Parkinson's disease.

Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable.

Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: early is not always better.

Development of a Chronic Care Model for Neurological Conditions (CCM-NC).

Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.

Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson's disease.

Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome.

Telemedicine in Parkinson's disease: A patient perspective at a tertiary care centre.

Independent application of montreal cognitive assessment/mini-mental state examination conversion.

Sequence of electrode implantation and outcome of deep brain stimulation for Parkinson's disease.

Knowledge of Parkinson's Disease in a Multiethnic Urban Asian Setting.

Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study.

Nonmotor features of Parkinson's disease subtypes.

Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.

Lithium Use in Older Adults is Associated with Increased Prescribing of Parkinson Medications.

Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease.

Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force.

Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.

Launching the movement disorders society genetic mutation database (MDSGene).

Inflammatory profile in LRRK2-associated prodromal and clinical PD.

Appendectomy in mid and later life and risk of Parkinson's disease: A population-based study.

The Danger of Not Treating Parkinson Disease Psychosis-Reply.

Reply letter to Jinnah "Locus pocus" and Albanese "Complex dystonia is not a category in the new 2013 consensus classification": Necessary evolution, no magic!

Regular Exercise, Quality of Life, and Mobility in Parkinson's Disease: A Longitudinal Analysis of National Parkinson Foundation Quality Improvement Initiative Data.

Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease.

Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer.

The financial burden of prescription drugs for neurological conditions in Canada: Results from the National Population Health Study of Neurological Conditions.

Antipsychotic Use and Physical Morbidity in Parkinson Disease.

What Would Dr. James Parkinson Think Today III: Measuring Health-Related Quality of Life.

Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease.

The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.

Mild cognitive impairment as a risk factor for Parkinson's disease dementia.

A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement.

Nonmotor Signs in Genetic Forms of Parkinson's Disease.

Treatable inherited rare movement disorders.

Anti-inflammatory drug use and progressive supranuclear palsy.

Health and Community-Based Services for Individuals with Neurological Conditions.

Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study.

Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers.

Initial cognitive changes in Parkinson's disease.

Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review.

Risk factors for non-motor symptoms in Parkinson's disease.

Emotion Detection Deficits and Decreased Empathy in Patients with Alzheimer's Disease and Parkinson's Disease Affect Caregiver Mood and Burden.

Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2.

The genetic nomenclature of recessive cerebellar ataxias.

Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson's disease.

Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health.

Reproducibility of data-driven Parkinson's disease subtypes for clinical research.

Brain tissue pulsatility is related to clinical features of Parkinson's disease.

Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests.

Antipsychotic Drug Dispensing in Older Adults With Parkinsonism.

Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review.

Educational Needs and Considerations for a Visual Educational Tool to Discuss Parkinson's Disease.

MDSGene: Closing Data Gaps in Genotype-Phenotype Correlations of Monogenic Parkinson's Disease.

Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease.

Risk of Parkinson's disease dementia related to level I MDS PD-MCI.

We are what we eat - editors' note on the role of diet in Parkinson's disease.

Reply to "Studying reproducibility of data-driven Parkinson's disease subtypes".

22q11.2 Deletion Syndrome-Associated Parkinson's Disease.

Concordance for Parkinson's disease in twins: A 20-year update.

Clinical Parkinson disease subtyping does not predict pathology.

Cognitive Complaints in Nondemented Parkinson's Disease Patients and Their Close Contacts do not Predict Worse Cognitive Outcome.

Reply to 'Neuropathological progression of clinical Parkinson disease subtypes'.

Recent developments in drug-induced movement disorders: a mixed picture.

Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.

Communication About OFF Periods in Parkinson's Disease: A Survey of Physicians, Patients, and Carepartners.

Understanding the links between cardiovascular disease and Parkinson's disease.

Nomenclature of Genetically Determined Myoclonus Syndromes: Recommendations of the International Parkinson and Movement Disorder Society Task Force.

Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?

Cervical dystonia incidence and diagnostic delay in a multiethnic population.

Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer's Disease, Parkinson's Disease, and Healthy Controls.